Ernesto M De Las Alas, MD in Everett, PA - Internal Medicine

Ernesto M De Las Alas, MD is a Internal Medicine physician based in Everett, Pennsylvania. Ernesto M De Las Alas is licensed to practice in Pennsylvania (license number MD016421E) and his current practice location is 10455 Lincoln Hwy, Everett, Pennsylvania. He can be reached at his office (for appointments etc.) via phone at (814) 623-6161.

NPI number for Ernesto M De Las Alas is 1558524587 and his current mailing address is 10455 Lincoln Hwy, Everett, Pennsylvania. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1558524587.

Contact Information

	Ernesto M De Las Alas, MD
	10455 Lincoln Hwy, Everett, PA 15537-7046
	(814) 623-6161
	Not Available

Physician's Profile

Full Name	Ernesto M De Las Alas
Gender	Male
Speciality	Internal Medicine
Location	10455 Lincoln Hwy, Everett, Pennsylvania
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1558524587
Provider Enumeration Date: 07/09/2008
Last Update Date: 07/09/2008

Medical Identifiers

Medical identifiers for Ernesto M De Las Alas such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1558524587	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207R00000X	Internal Medicine	MD016421E (Pennsylvania)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Ernesto M De Las Alas is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Ernesto M De Las Alas, MD 10455 Lincoln Hwy, Everett, PA 15537-7046 Ph: (814) 623-6161	Ernesto M De Las Alas, MD 10455 Lincoln Hwy, Everett, PA 15537-7046 Ph: (814) 623-6161

News Archive

Patheon second-quarter total revenues increase 4.8% to $175.4 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today its results for the second quarter and six months ended April 30, 2010. Total revenues for the second quarter were $175.4 million or 4.8% higher than the same period last year.

Individuals who do not speak English at home less likely to receive CRC: Researchers

Researchers from Boston Medical Center and Boston University School of Public Health have found that individuals who do not speak English at home are less likely to receive colorectal cancer screenings as compared to those who do speak English at home. The findings, which currently appear on-line in the Journal of General Internal Medicine, suggest that patient-provider language barriers play a role in health-care disparities, and that providers should promote the importance of CRC screening to non-English speaking patients.

Partners Urgent Care announces opening of first urgent care center in Brookline, Massachusetts

Partners Urgent Care today announced the opening of its first urgent care center in the town of Brookline, Massachusetts at 1285 Beacon Street. Partners Urgent Care is a collaboration between Partners HealthCare, an integrated health care system founded by Massachusetts General Hospital and Brigham and Women's Hospital, and MedSpring Urgent Care.

Increased signaling by sonic hedgehog protein can inhibit LID in Parkinson's patients

Levodopa, or L-dopa, is considered the most effective treatment for Parkinson's disease today. After a few years of treatment, however, almost all patients develop a debilitating side-effect called L-dopa induced dyskinesia, or LID, which causes involuntary movements in the limbs, face, and torso. Deep brain stimulation can alleviate LID, but the procedure is highly invasive and not all patients are eligible.

FDA approves J&JPRD's PANCREAZE NDA

Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) announced that the U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for PANCREAZE™ (pancrelipase) delayed-release capsules for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Exocrine pancreatic insufficiency is the inability to properly digest and absorb food due to a lack of enzymes made by the pancreas that are important in the digestion of fats, proteins, and sugars.

Internal Medicine Doctors in Everett, PA

Nancy Kenney, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 311 Hospital Dr, Suite 2, Everett, PA 15537 Phone: 814-623-7855
Muzammil Khan, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10455 Lincoln Hwy, Everett, PA 15537 Phone: 814-623-6161

Ernesto M De Las Alas, MD - Internal Medicine in Everett, PA